Trials / Completed
CompletedNCT04246489
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 146 (actual)
- Sponsor
- EMD Serono Research & Development Institute, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study was to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bintrafusp alfa | Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, death, unacceptable toxicity and study withdrawal. |
Timeline
- Start date
- 2020-03-30
- Primary completion
- 2022-04-05
- Completion
- 2022-12-14
- First posted
- 2020-01-29
- Last updated
- 2023-10-23
- Results posted
- 2023-05-09
Locations
73 sites across 12 countries: United States, Argentina, Australia, Belgium, Brazil, China, France, Hungary, Japan, Russia, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04246489. Inclusion in this directory is not an endorsement.